Cardio Diagnostics Introduces Molecular Precision to Address Blind Spots in Coronary Heart Disease Detection

Coronary heart disease (CHD) remains the leading cause of death in the United States, but the tools doctors have long relied on to detect it early are proving less reliable than many patients assume, according to Cardio Diagnostics Holdings (NASDAQ: CDIO). The company reports that approximately 50% of individuals with coronary heart disease do not present with traditional risk factors, and conventional risk calculators have an average sensitivity of only 39%. In practical terms, this means that many who appear healthy may still develop CHD and suffer preventable cardiac events such as a heart attack.

For decades, cardiovascular risk assessment has centered on a checklist of factors—cholesterol levels, blood pressure, smoking history, diabetes status, family history, and weight. While these factors matter and are useful pieces of the puzzle, they were never designed to capture the full biological picture of how heart disease develops. What makes CHD numbers particularly troubling, the company emphasizes, is that so much of this is preventable.

Cardio Diagnostics has developed clinical tests rooted in epigenetics and genetics, fields that examine how genes are expressed and regulated at the molecular level. These tests aim to identify molecular signatures of CHD even in individuals who lack traditional risk factors, potentially filling a critical blind spot in current screening practices.

The implications of this announcement are significant for both clinical practice and public health. If molecular precision can improve early detection, it could lead to earlier interventions and better outcomes for millions of patients. The company’s approach may also reduce the number of unexpected heart attacks among those considered low-risk by conventional standards.

Investors and healthcare professionals can find the latest news and updates relating to Cardio Diagnostics in the company’s newsroom at https://ibn.fm/CDIO. Full terms of use and disclaimers are available on the InvestorBrandNetwork website at http://IBN.fm/Disclaimer.

This article contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially. Undue reliance should not be placed on these forward-looking statements in making an investment decision. All parties undertake no duty to update this information unless required by law.

This news story relied on content distributed by NewMediaWire. Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Cardio Diagnostics Introduces Molecular Precision to Address Blind Spots in Coronary Heart Disease Detection.

The post Cardio Diagnostics Introduces Molecular Precision to Address Blind Spots in Coronary Heart Disease Detection appeared first on citybuzz.